Clinical experience with 100 consecutive patients treated with
Lu-177-labeled PSMA-I&T radioligand therapy for metastatic
castration-resistant prostate cancer: Final analysis
Document type:
Meeting Abstract
Author(s):
Tauber, R. L.; Knorr, K.; Schwaiger, S.; Retz, M.; Maurer, T.; D'Alessandria, C.; Wester, H-J.; Gschwend, J.; Weber, W.; Schwaiger, M.; Heck, M. M.; Eiber, M.